ReviewNanomedicine (London, England)2025
Current treatments and the future of nanomedicine in hepatitis C.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine in maternal viral infections: advancing prenatal therapies for fetal protection.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advances in hepatitis C treatment, the disease remains a significant global health burden, with an estimated 1 million new infections in 2022. Upon infection, the disease will progress to chronic infection, leading to cirrhosis, fibrosis, hepatocellular carcinoma, and end-stage liver disease. Although treatments (Direct-Acting Antiretrovirals) are available, they cannot completely clear the virus. In this review, we summarized the current therapies used to treat hepatitis C, followed by an analysis of the future application of nanomedicine to combat this disease. We compile information related to gene silencing, the nanodelivery of specific drugs, and the trials associated with vaccine development. Although many studies have been successful in animal models, further research is needed to develop a cure or vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.